ChinaBio® LLC and BioCentury Publications, Inc. announced they have agreed to a collaboration that will make news about China’s rapidly growing biopharma industry more readily available to a global audience. BioCentury, the internationally respected source of biopharma business intelligence, will be a gateway to articles from ChinaBio® Today, the most widely read source of China-focused pharmaceutical news.

Beginning today, BioCentury will feature ChinaBio® Today’s “Week in Review” summary of each week’s major stories at www.biocentury.com. Other major stories from ChinaBio also will be made available on BioCentury’s website in their complete form.

According to ChinaBio's Shanghai research team, China is now the third-largest pharmaceutical market in the world, growing at over 20% per year. Chinese life science companies generated over $5 billion in proceeds from IPOs in 2011, and raised nearly $1 billion in venture capital and private equity funding. There were also over 60 partnering deals, many between Western and Chinese companies, with several reaching total potential deal values of over $100 million.

“China is now an integral part of any life science company’s strategy, and ChinaBio® Today together with BioCentury will detail the development of this rapidly growing market, ” said Greg Scott, CEO and Founder of ChinaBio®. “BioCentury is globally respected for its analysis of the life sciences, and we are honored to have them share our content on China’s dynamic pharma industry.”

“BioCentury respects ChinaBio's efforts to provide access to China's burgeoning biopharma space via its research, conferences and publications such as ChinaBio® Today,” said David Flores, President & CEO of BioCentury. “We expect our readers to find ChinaBio’s coverage of news and events to be indispensable for understanding business opportunities in China.”

ChinaBio® Today is available at www.chinabiotoday.com and BioCentury at www.biocentury.com.